Suppr超能文献

在内镜黏膜切除术中用新型口服抗凝剂替代华法林:一项多中心、开放标签、随机对照试验。

Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial.

作者信息

Yamada Takuya, Kada Akiko, Uraoka Toshio, Kuwai Toshio, Watanabe Noriko, Sasaki Yoshihiro, Mabe Katsuhiro, Takahashi Yasuo, Kagaya Takashi, Kimura Toshihisa, Hamada Hiroshige, Saito Akiko M, Harada Naohiko

机构信息

Department of Gastroenterology, National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.

出版信息

BMJ Open Gastroenterol. 2017 Sep 15;4(1):e000152. doi: 10.1136/bmjgast-2017-000152. eCollection 2017.

Abstract

INTRODUCTION

This randomised controlled trial aims to compare the efficacy of warfarin replacement with apixaban without postoperative resumption of heparin with that of conventional heparin bridging in patients taking warfarin and scheduled to undergo endoscopic mucosal resection (EMR): specifically, by checking for reduction in proportion of postoperative bleeding following EMR.

METHODS AND ANALYSIS

The multicentre, open-label randomised parallel-group, controlled intervention study regards patients taking warfarin who are scheduled to undergo colon EMR. Enrolled patients have been taking oral warfarin for non-valvular atrial fibrillation or venous thrombosis on an outpatient basis, and have been found to have a colorectal polyp (including adenoma or early-stage cancer) for which EMR was indicated. They are assigned to one of two groups. The primary endpoint is proportion of postoperative bleeding. The secondary endpoints are hospital stay length, therapeutic endoscopy outcomes such as proportion of en bloc resection, proportion of perforation, proportion of intraoperative bleeding, incidence of cerebral infarction/systemic embolism events, incidence of adverse events and serious adverse events, and proportion of postoperative therapeutic endoscopy.

ETHICS AND DISSEMINATION

This trial was approved by the National Hospital Organization Central Review Board for Clinical Trials (19 April 2016).

DISCUSSION

The paucity of reports with high evidence levels was considered problematic when the Japan Gastroenterological Endoscopy Society's gastroenterological endoscopy guidelines were revised in 2012. The results of this trial will have high medical significance, as its data could serve as the basis for revisions in the next edition of the guidelines.

TRIAL REGISTRATION NUMBER

This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) accepted from the International Committee of Medical Journal Editors (ICMJE). UMIN000021947; Pre-results.

摘要

引言

本随机对照试验旨在比较在服用华法林且计划接受内镜黏膜切除术(EMR)的患者中,用阿哌沙班替代华法林且术后不恢复使用肝素与传统肝素桥接疗法的疗效;具体而言,是通过检查EMR术后出血比例的降低情况来进行比较。

方法与分析

这项多中心、开放标签、随机平行组对照干预研究针对计划接受结肠EMR的服用华法林的患者。入选患者因非瓣膜性心房颤动或静脉血栓形成而在门诊口服华法林,且被发现患有指示需进行EMR的大肠息肉(包括腺瘤或早期癌症)。他们被分配到两个组中的一组。主要终点是术后出血比例。次要终点包括住院时间、治疗性内镜检查结果,如整块切除比例、穿孔比例、术中出血比例、脑梗死/全身性栓塞事件发生率、不良事件和严重不良事件发生率以及术后治疗性内镜检查比例。

伦理与传播

本试验经国立医院组织临床试验中央审查委员会批准(2016年4月19日)。

讨论

2012年日本胃肠内镜学会的胃肠内镜指南修订时,证据水平高的报告匮乏被认为是个问题。本试验结果将具有很高的医学意义,因为其数据可作为下一版指南修订的依据。

试验注册号

本试验在大学医院医学信息网络临床试验注册中心(UMIN-CTR)注册,该中心接受国际医学期刊编辑委员会(ICMJE)的认可。UMIN000021947;预结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5e3/5623266/8f32936823c9/bmjgast-2017-000152f01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验